Results 181 to 190 of about 4,881,979 (331)

Hot line 1

Netherlands Heart Journal, 2007
openaire   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma. [PDF]

Nature
Zhang T, Zhao W, Wirth C, Díaz-Gay M, Yin J, Cecati M, Marchegiani F, Hoang PH, Leduc C, Baine MK, Travis WD, Sholl LM, Joubert P, Sang J, McElderry JP, Antony M, Klein A, Khandekar A, Hartman C, Rosenbaum J, Colón-Matos FJ, Miraftab M, Saha M, Lee OW, Jones KM, Caporaso NE, Wong MP, Leung KC, Hsiung CA, Chen CY, Edell ES, Santamaría JM, Schabath MB, Yendamuri SS, Manczuk M, Lissowska J, Świątkowska B, Mukeria A, Shangina O, Zaridze D, Holcatova I, Mates D, Milosavljevic S, Savic M, Bossé Y, Rothberg BEG, Christiani DC, Gaborieau V, Brennan P, Liu G, Hofman P, Homer R, Yang SR, Pesatori AC, Consonni D, Yang L, Zhu B, Shi J, Brown K, Rothman N, Chanock SJ, Alexandrov LB, Choi J, Cardelli M, Lan Q, Nowak MA, Wedge DC, Landi MT.   +67 more
europepmc   +1 more source

LINE-1 retrotransposition is a recurrent cause of MET exon 14 skipping in cancer [PDF]

Jennifer A. Karlow, Callan O'connor, Radwa Sharaf, Dean C. Pavlick, Andrej Savol, Christopher Darcy, Akshay Kakumanu, William Camara, Matthew Walsh, Tyler Janovitz, M. Kelley, Christine N Serway, Jerry W. Mitchell, Julia A. Elvin, Meagan Montesion, H. Burns Kathleen, G. Frampton   +16 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Role of LINE-1 in the nervous system and neurological disorders. [PDF]

Chin Med J (Engl)
Hu H, Lu X, Zhong R, Liu X, Wei J, Duan C, Sun N.   +6 more
europepmc   +1 more source

Supplementary Tables and Figures 1 from First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

Peter Schmid, Nicholas C. Turner, Carlos H. Barrios, Steven J. Isakoff, Sung‐Bae Kim, Marie‐Paule Sablin, Shigehira Saji, Peter Savas, Gregory A. Vidal, Mafalda Oliveira, Joyce O’Shaughnessy, Antoîne Italiano, Enrique Espinosa, Valentina Boni, Shane White, Beatriz Rojas, Ruffo Freitas‐Júnior, Y.S. Chae, Igor Bondarenko, Jieun Lee, Cesar Torres Mattos, Jorge Luis Martinez Rodriguez, Lisa H. Lam, Surai Jones, Sarah-Jayne Reilly, Xiayu Huang, Kalpit Shah, Rebecca Dent   +27 more
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Post-Transcriptional Control of LINE-1 Retrotransposition by Cellular Host Factors in Somatic Cells [PDF]

, 2016
Gaël Cristofari, Javier G. Pizarro
core   +1 more source